Recursion Pharmaceuticals (RXRX) Free Cash Flow (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Free Cash Flow came in at -$81.4 million in Q1 2026, up 39.19% YoY from -$58.5 million in Q1 2025, and down 99.17% on a QoQ basis from -$40.8 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Free Cash Flow (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Free Cash Flow data on file, last reported at -$81.4 million in Q1 2026.
- Quarterly Free Cash Flow rose 39.19% year-over-year to -$81.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$319.4 million (up 19.69% YoY) and the FY2025 annual result came in at -$371.8 million, changed 0.28% from the prior year.
- Free Cash Flow fell to -$81.4 million in Q1 2026, from -$40.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $73.0 million in Q1 2022 to a low of -$133.8 million in Q1 2025.
- A 5-year average of -$71.2 million and a median of -$74.8 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 332.19% — and 2023, when it plunged 207.45%.
- Tracing RXRX's Free Cash Flow over 5 years: stood at -$42.2 million in 2022, then slumped by 103.65% to -$86.0 million in 2023, then tumbled by 35.68% to -$116.7 million in 2024, then surged by 65.01% to -$40.8 million in 2025, then slumped by 99.17% to -$81.4 million in 2026.
- The last three Free Cash Flow figures came in at -$81.4 million (Q1 2026), -$40.8 million (Q4 2025), and -$122.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -105.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -105.99 Mn |
| Jun 30, 2026 | -105.99 Mn |
| Mar 31, 2026 | -81.36 Mn |
| Mar 31, 2026 | -81.36 Mn |
| Dec 31, 2025 | -40.85 Mn |
| Dec 31, 2025 | -40.85 Mn |
| Sep 30, 2025 | -122.32 Mn |
| Sep 30, 2025 | -122.32 Mn |
| Jun 30, 2025 | -74.85 Mn |
| Jun 30, 2025 | -74.85 Mn |
| Mar 31, 2025 | -133.79 Mn |
| Mar 31, 2025 | -133.79 Mn |
| Dec 31, 2024 | -116.73 Mn |
| Dec 31, 2024 | -116.73 Mn |
| Sep 30, 2024 | -71.07 Mn |
| Sep 30, 2024 | -71.07 Mn |
| Jun 30, 2024 | -76.12 Mn |
| Jun 30, 2024 | -76.12 Mn |
| Mar 31, 2024 | -108.95 Mn |
| Mar 31, 2024 | -108.95 Mn |